Cellular immunotherapy using T cells engineered to express chimeric antigen receptors targeting CD19 (CART19) leads to long-term remission in patients with B-cell malignancies [1] [2] [3] [4] [5] .
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Main Text
The success of CD19-directed CAR T cells (CART19) is significantly limited by lack of disease response (primary resistance) and disease relapse after initial response (acquired resistance) [1] [2] [3] [4] [5] in some patients. To identify the mechanisms that enable acquired resistance to CART19, we performed genome-wide CRISPR/Cas9-based knockout screens 6 in the CD19+ human ALL cell line Nalm6 (Figure 1a) . Using the Brunello short-guide RNA (sgRNA) library 7 , we generated a pool of Nalm6 in which each cell had been edited for loss of function of a single gene. We combined Brunello-edited Nalm6 cells with CART19 and monitored co-cultures for the emergence of resistant leukemic clones. GFP-labeled Nalm6 initially became undetectable after three days, indicating robust early cytotoxicity by CART19 cells, but recurred after 28 days (Extended Data Figure 1) . Next-generation sequencing demonstrated that the single mostenriched guide target in resistant Nalm6 cells was CD19 (Figure 1b ). This finding is consistent with the clinical observation that antigen loss is the primary cause of acquired resistance (relapse) after initial CART19-induced remission [8] [9] [10] , and validated our screening approach.
While several mechanisms of acquired resistance by antigen silencing have been described 9-11 , less is known about the mechanisms of primary resistance. Nearly 1 in 5 patients with CD19+
ALL are primarily refractory to CART19 1, 3 , indicating that some tumors are intrinsically resistant to this therapy. To identify the processes responsible for primary resistance, we combined Brunello-edited Nalm6 with CART19 and collected cells after 24 hours of co-culture.
In this short-term screening system, sgRNA sequencing demonstrated enrichment of sgRNAs targeting several pro-apoptotic death receptor signaling molecules (FADD, BID, CASP8 and TNFRSF10B), and depletion of guides targeting several anti-apoptotic molecules (CFLAR, TRAF2 and BIRC2) (Figure 1c) . Gene set enrichment analysis (GSEA) identified a strong association between enriched or depleted sgRNAs and apoptotic signaling (false discovery rate P=1.13x10 -8 , Figure 1d) . Notably, all sequenced sgRNAs in this pathway are specifically involved in death receptor-driven apoptosis. These findings suggest that ALL death receptor signaling is a key regulator of resistance to CART19.
To confirm the functional significance of impaired tumor death receptor signaling, we focused on two targets: Fas-associated protein with death domain (FADD), which serves as a membrane- 4 proximal adaptor to all pro-apoptotic death receptors, and BH3 interacting-domain death agonist (BID), which is activated downstream of FADD and initiates mitochondrial activity that induces apoptosis 12 Figures 4g-h) . Remarkably, CART19 treatment led to a marginal improvement in median survival (4-5 days) in animals with KO tumors (Figures 1f-g ), demonstrating that disruption of a single death receptor signaling gene can lead to rapid CART19 failure in vivo.
These data indicate that disruption of death receptor signaling in ALL enables specific resistance to CAR T cells, and that death receptor engagement is required for CART19 activity. Table 2) . Together, these findings suggest that exposure to leukemia cells that are deficient in death receptor signaling leads to global programmatic changes in CART19 that shares many features with classical T cell exhaustion, 14, 16, 20 but also induces unique epigenetic changes in the setting of persistent CAR engagement.
In light of these observations, we investigated the association between tumor expression of death receptor genes and clinical outcomes after treatment with tisagenlecleucel, a clinical CD19-directed CAR T cell product 1 . We evaluated available leukemia-infiltrated bone marrow samples collected prior to treatment from patients who had either durable (>1 year) complete remissions (CR, n = 17) or no response (NR, n = 8) from two multi-center clinical trials of tisagenlecleucel for relapsed pediatric ALL (ClinicalTrials.gov identifiers NCT02435849 and NCT02228096).
Using the KEGG pathway database, we identified the pro-apoptotic genes specifically involved in either intrinsic apoptosis or death receptor signaling to generate two distinct gene sets for 8 analysis (Supplementary Table 1 and Methods). Using normalized expression data from our patient samples, we generated two gene set scores ("intrinsic apoptosis signature" and "death receptor signature") that represented overall expression of pro-apoptotic genes in each pathway.
We found no difference in expression of the intrinsic apoptosis signature between CRs and NRs (Extended Data Figures 10a-b) . In contrast, non-responders had lower expression of death receptor genes and significantly lower death receptor signature scores than durable responders (P=0.0126, Figure 3a- (Figure 3b) .
Tisagenlecleucel expansion and persistence are highly associated with clinical response 26, 27 and based on our pre-clinical observations we hypothesized that exposure to death receptor-impaired leukemia may correlate with dysfunctional T cell expansion and persistence in patients.
Pharmacokinetic analysis revealed reduced tisagenlecleucel expansion and shorter persistence in patients with death receptor signature scores below the cutoff (low scores) as compared to patients with scores above the cutoff (high scores) (Figure 3c-d) . We further explored clinical outcomes in this patient cohort and found striking differences in overall survival between patients with high and low scores (Figure 3e , P<0.0001). Notably, 5 of 6 patients with low scores died soon after therapy. Given that clinical samples were not collected in a manner that allowed analysis of purified leukemic blasts, we adjusted gene set scores for the extent of blast involvement in patient marrow (see Methods) and repeated this analysis. These adjusted gene set scores were also highly-associated with clinical outcome, tisagenlecleucel expansion and persistence, and overall patient survival (Extended Data Figure 10c-f) . Multivariate logistic regression analysis identified that the association between death receptor signature score and clinical response was highly mediated by the association between death receptor signature score and T cell expansion, mirroring our in vitro observations of impaired T cell expansion upon exposure to death receptor-impaired Nalm6.
Until now, primary resistance to CART19 was presumed to be a result of intrinsic T cell defects 28, 29 , leading to extensive efforts to use heathy donor (i.e. allogeneic donor or "universal" donor) T cells as a substrate for CAR T cell manufacturing. Our data offer a model in which 9 tumor-intrinsic biology contributes to observed therapeutic failure in a manner that is orthogonal to chemotherapy resistance (Figure 3f ). These data suggest that antigen persistence resulting from slow response kinetics may also lead to progressive T cell dysfunction, tilting the balance in favor of primary resistance to CART19. Additional studies investigating the role of death receptor gene expression as a clinical biomarker may allow improved patient selection for CAR therapy products and trials. Further, development of methods to overcome death receptormediated resistance may significantly improve clinical outcomes after engineered cell therapy.
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Methods
Brunello guide library screens: The Brunello sgRNA knockout plasmid library was designed and produced as previously described [6] [7] . For generation of the lentiviral knockout library, four 15cm dishes of HEK293T cells (ATCC ACS-4500) were seeded at ~40% confluence the day before transfection in D10 media (DMEM supplemented with 10% fetal bovine serum). One hour prior to transfection, media was removed and 13mL of pre-warmed reduced serum OptiMEM media was added to each flask. For each dish, 20µg of plasmid library, 10µg of pVSVg, and 15µg of psPAX2 (Addgene) were diluted in 2mL OptiMEM. 100µL of Lipofectamine 2000 (Invitrogen)
was diluted in 2mL OptiMEM and after a 5min incubation was added to the diluted DNA mixture. The complete mixture was incubated for 20min before being added to cells. After 6h, the media was changed to 15mL D10. Media containing lentiviral particles was removed after 48h and stored in 1mL aliquots at -80°C. To find optimal virus volumes to achieve an MOI of 0.2-0.3, each viral production was individually titrated. Briefly, 2x10 6 cells were plated into each well of a 12 well plate, and varying volumes of virus (between 0 and 160µL) were added. Cells were counted and each well was split into two plates and diluted 1:10; one plate underwent selection with puromycin (1µg/mL). After 48h, each well was counted and viability assessed to determine percent transduction (calculated as cell count from the replicate with puromycin divided by cell count from the replicate without puromycin). The virus volume yielding a MOI closest to 0.2 was chosen for large-scale screening. For long-term depletion screening, 2x10 8 Nalm6 cells (edited as described above) were combined with 5x10 7 CART19 cells or control T cells (effector:target ratio 1:4) and co-cultured in standard culture media; 5x10 7 control Nalm6 cells were frozen for genomic DNA analysis. Each condition was established in duplicate, and co-cultures were monitored by flow cytometry over time and maintained at a concentration of 1x10 6 cells/mL. Cultures were monitored until Nalm6 recurred in selection cultures, at which time dead cells were removed using a Dead Cell Removal magnetic bead kit (Miltenyi) and living cells were frozen for genomic DNA analysis. Short-term screening co-cultures were established in the same manner, however dead cell removal and live cell collection was performed after 24h of co-culture.
Genomic DNA extraction and guide sequencing: From each screening culture, 3x10 7 -5x10 7 were flash frozen as dry cell pellets. At time of DNA extraction, 6 mL of NK Lysis Buffer (50 11 mM Tris, 50 mM EDTA, 1% SDS, pH 8) and 30μL of 20mg/mL Proteinase K were added to the frozen cell sample and incubated at 55°C overnight. The following day, 30μL of 10mg/mL RNase A, diluted in NK Lysis Buffer to 10mg/mL and then stored at 4°C, was added to the lysed sample, which was then inverted 25 times and incubated at 37°C for 30min. Samples were cooled on ice before addition of 2mL of pre-chilled 7.5M ammonium acetate to precipitate proteins. The samples were vortexed at high speed for 20s and then centrifuged at ≥ 4,000×g for 10min. After the spin, a tight pellet was visible in each tube and the supernatant was carefully decanted into a new 15mL tube. 6mL 100% isopropanol was added to the tube, inverted 50 times and centrifuged at ≥ 4,000×g for 10min. Genomic DNA (gDNA) was visible as a small white pellet in each tube. The supernatant was discarded, 6mL of freshly prepared 70% ethanol was added to the tube and inverted 10 times and centrifuged at ≥4,000×g for 1min. The supernatant was discarded by pouring; the tube was briefly spun, and remaining ethanol was removed using a pipette. After air drying for 10-30min, 500μL of 1x TE buffer was added, the tube was incubated at 65°C for 1h and at room temperature overnight to fully resuspend the DNA. The next day, the gDNA samples were vortexed briefly, and gDNA concentration was measured.
To measure the distribution of sgRNA within each screen arm, we used Illumina Next
Generation Sequencing applied to an amplicon generated from a single targeted PCR of the integrated sgRNA cassette 6 . Briefly, we used all collected gDNA (1000x coverage) divided into 100µL PCR reactions with 5µg of DNA per reaction. We used Takara ExTaq DNA Polymerase and the default mix protocol with the following PCR program: (95 2min, (98 10sec, 60 30sec, 72 30sec) x 24, 72 5min). PCR products were gel purified using the QiaQuick gel extraction kit (Qiagen). The purified, pooled library was then sequenced on a HiSeq4000 with ~5% PhiX added to the sequencing lane. Quality assessment was done by qubit (for concentration), bioAnalyzer (for size distribution) and Kapa Library Quantification (for clusterable molarity).
Genome-wide screening data analysis: To count the number of reads associated with each sgRNA in each Fastq file, we first extracted the sgRNA targeting sequencing using a regular expression containing the three nucleotides flanking each side of the sgRNA 20bp target. sgRNA spacer sequences were then aligned to a pre-indexed Brunello library (Addgene) using the shortread aligner 'bowtie' using parameters (-v 0 -m 1). Data analysis was performed using custom R 12 scripts. Using the guide sequencing data, we analyzed enrichment and depletion of guide RNAs with the Model-based Analysis of Genome-wide CRISPR/Cas9 Knockout (MAGeCK) algorithm using the maximum likelihood estimation (MLE) module 32, 33 . In our long-term screen, we found that over 25% of all sequenced reads in the experimental (CART19) selection condition originated from sgRNAs targeting CD19. This led to a highly skewed sgRNA distribution in the sequencing data, preventing meaningful statistical analysis of other targets identified using the MAGeCK algorithm.
CRISPR/Cas9-guide design, genomic engineering and indel detection: CRISPR sgRNAs were designed using software integrated into Benchling (http://Benchling.com). For each target gene, six sgRNA sequences were designed to target early exon sequences, and in vitro transcribed using the GeneArt Precision gRNA Synthesis Kit (Invitrogen) for screening. Cells were electroporated using the Lonza 4D-Nucleofector Core/X Unit. Nalm6 cells were electroporated using the SF Cell Line 4-D Nucleofector Kit, and primary T cells were electroporated using the P3 Primary Cell 4-D Kit (Lonza). For Cas9 and sgRNA delivery, the ribonucleoprotein (RNP) complex was first formed by incubating 10µg of TrueCut Cas9 Protein V2 (Lonza) with 5µg of sgRNA for 10-30min at room temperature. Cells were spun down at 300 xg for 10min and resuspended at a concentration of 3-5x10 6 cells/100µL in the specified buffer. The RNP complex, 100µL of resuspended cells, and 4µL of 100µM IDT Electroporation Enhancer (IDT)
were combined and electroporated. Pulse codes EO-115 and CV-104 were used for primary T cells and Nalm6 cells, respectively. After electroporation, the cells were incubated in standard media at a 5x10 6 cells/mL at 30ºC for 48h, then cultured at 37ºC for the duration of experimental procedures. TIDE (Tracking of Indels by DEcomposition) analysis was used to detect knock out (KO) efficiency at the genomic level 32 . Genomic DNA from electroporated cells was isolated (Qiagen DNeasy Blood & Tissue Kit) and 200-300ng were PCR amplified using Accuprime Pfx SuperMix and 10µM forward/reverse primers flanking the region of interest. Primers were designed such that the amplicon was at a target size ~1 kb. PCR products were gel purified and sequenced, and trace files were analyzed using Desktop Genetics software (tide.deskgen.com, Desktop Genetics) to determine KO efficiency. R 2 values were calculated, reflecting goodness of fit after non-negative linear modeling by TIDE software 34 . See Supplemental Table 3 for sgRNA sequences and sequencing primer sequences. 13 General cell culture: Unless otherwise specified, cells were grown and cultured at a concentration of 1x10 6 cells/mL of standard culture media (RPMI 1640 + 10% FCS, 1%
penicillin/streptomycin, 1% HEPES, 1% non-essential amino acids) at 37C in 5% ambient CO2.
All co-culture studies were performed an effector cell to target cell ratio of 1:4, unless otherwise and CD8 cells were combined at a 1:1 ratio, and activated using CD3/CD28 stimulatory beads (Thermo-Fisher) at a ratio of 3 beads/cell and incubated at 37C overnight. The following day, CAR lentiviral vectors were added to stimulatory cultures at an MOI between 4-6. Beads were removed on day 6 of stimulation, and cells were counted daily until growth kinetics and cell size demonstrated they had rested from stimulation.
Bioluminescence-based cell survival assays: Click beetle green (CBG)-engineered cell survival was measured using bioluminescent quantification. D-luciferin potassium salt (Perkin-Elmer) was added to cell cultures (final concentration 15g/mL) and incubated at 37C for 10min.
Bioluminescent signal was detected using a BioTek Synergy H4 imager, and signal was analyzed using BioTek Gen5 software. Percent specific lysis was calculated using a control of target cells without effectors.
14 Flow cytometry: Cells were resuspended in FACS staining buffer (PBS + 3% fetal bovine serum) using the following antibodies: CD3 (clone OKT3, eBiosciences), CD4 (clone OKT4, eBiosciences), CD8 (clone SK1, BD), PD-1 (clone J105, eBiosciences), TIM3 (clones F38-2E2, BioLegend), Tbet (clone 4B10, eBiosciences). CD19 CAR was detected using an anti-idiotype antibody provided by Novartis Pharmaceuticals. All changes in overall tumor or T cell counts reflect changes in absolute cell counts, which were determined using CountBright absolute counting beads (ThermoFisher). Cell viability was established using Live/Dead Aqua fixable staining kit (ThermoFisher), and data were acquired on an LSRII Fortessa Cytometer (BD). All data analysis was performed using FlowJo 9.0 software (FlowJo, LLC).
Cytokine and cytolytic molecule quantification: Human cytokine quantification was performed FlexMAP 3D quantification instrument, and analysis was done using xPONENT software. Data quality was determined by ensuring the standard curve for each analyte had a 5P R 2 value > 0.95 with or without minor fitting using xPONENT software. To pass assay technical quality control, the results for two controls in the kit were required to be within the 95% confidence interval provided by the vendor for >25 of the tested analytes. We established in vitro quantification of granzyme B (antibody sets from R&D Systems) and perforin (antibody sets from MABTECH), using ELISA substrate ADHP from Cayman Chemical, assay plates from E&K Scientific, and substrate plates from Greiner Bio-One. All ELISA reagents were prepared according to the protocols for DuoSet ELISA except for Color Reagent B, which was supplemented with ADHP at 100M. Instead of coating the capture antibody to the wells of the ELISA plate, it was coated on the surfaces of macrospheres, which enabled the measurement of both analytes using 100l of cell supernatant (collected as described above). Assays were set up using bead-strips in assay plates based on an assay map following the protocol for antibody sets. At the end of the assay, one substrate plate per 12 bead-strips for each analyte was prepared by adding 100l/well of 15 substrate solution (1:1 of color reagent A and ADHP). Each bead-strip was placed in one column of the substrate plate according to the assay map. Color development was for 10 to 30 mins.
Plates were read on a FLUO STAR OMEGA instrument using fluorescent channel at 530 nm (excitation) and 590 nm (emission). Data were analyzed using Omega Data Analysis software.
Xenograft mouse models: 6-10 week old NOD-SCID-γc -/-(NSG) mice were obtained from the Jackson Laboratory and maintained in pathogen-free conditions. Animals were injected via tail vein with 1x10 6 WT, BID KO or FADD KO Nalm6 cells in 0.2mL sterile PBS. On day 7 after tumor delivery, 5x10 5 T cells (control or CAR+) were injected via tail vein in 0.2mL sterile PBS.
Animals were monitored for signs of disease progression and overt toxicity, such as xenogeneic graft-versus-host disease, as evidenced by >10% loss in body weight, loss of fur, diarrhea, conjunctivitis and disease-related hind limb paralysis. Disease burdens were monitored over time using a the Xenogen IVIS bioluminescent imaging system, as previously described 13 .
RNA sequencing and analysis: RNA-seq libraries were made following the previously established SMARTseq2 protocol 35 . Briefly, total RNA was extracted using Qiazol (Qiagen) from 300 CART19 cells and recovered by RNA Clean and Concentrator spin columns (Zymo)
followed by incubation with Oligo-dT. The transcription reaction was carried out on 100pg of cDNA for 1min at 55°C. Libraries were uniquely barcoded 36 and amplified for 14 cycles.
Fragment size distribution was verified, and paired-end sequencing (2 x 75 bp reads) was carried out on an Illumina NextSeq 500.
Raw reads were mapped to the GRCh37/hg19 genome assembly using the RNA-seq aligner STAR (version 2.5.4b) 37 . The algorithm was given known gene models provided by GENCODE (release_27_hg19, www.gencodegenes.org) to achieve higher mapping accuracy. Quantification was also performed by STAR using the --quantMode GeneCounts flag. Raw counts were normalized (TMM normalization implemented in edgeR, followed by the voom transformation).
Lastly the Bioconductor package limma was used to assess differential expression using linear models. Genes with differential expression at a false discovery rate (FDR) < 0.05 and a log fold change (LFC) > 0.5 between replicates were considered for further analysis. Visualization was performed using the R package ggplot2. 16 ATAC sequencing: Omni ATAC-seq libraries were made as previously described 38 . Briefly, nuclei were isolated from 50,000 sorted CART19 cells, followed by the transposition reaction using Tn5 transposase (Illumina) for 30 minutes at 37°C with 1000rp mixing. Purification of transposed DNA was completed with DNA Clean and Concentrator (Zymo) and fragments were barcoded with ATAC-seq indices 36 . Final libraries were double size selected using AMPure beads prior to sequencing. Paired-end sequencing (2 x 75 bp reads) was carried out on an Illumina NextSeq 500 platform. Adapters were trimmed using attack (version 0.1.5, https://atactk.readthedocs.io/en/latest/index.html), and raw reads were aligned to the GRCh37/hg19 genome using bowtie 39 with the following flags: --chunkmbs 2000 --sam --best --strata -m1 -X 2000. MACS2 40 was used for peak calling with an FDR cutoff of 0.05.
Downstream analysis and visualization was done using HOMER 41 and deepTools2 42 .
Apoptotic pathway gene set development: Using the Kyoto Encyclopedia of Genes and Genomes (KEGG) "Apoptosis" pathway (hsa04210), we established two distinct gene set signatures. We determined to which pathway each gene belonged, either extrinsic (death receptor-dependent) or intrinsic (death receptor-independent) apoptosis. Genes that did not fall into either pathway (ie.
nuclear factor kappa-light-chain-enhancer of activated B cells-associated, nerve-growth factorassociated) 43 were excluded. Genes were then classified for activity, either pro-apoptotic or antiapoptotic, and pro-apoptotic genes were included in gene sets.
Evaluation of clinical specimens: Bone marrow (BM) specimens were collected from patients enrolled in two multi-center clinical trials (NCT02435849/ELIANA and NCT02228096/ENSIGN). All aspects of this study were approved by the Institutional Review Board at each participating institution. All relevant ethical regulations were complied with in this manuscript, and informed consent obtained at time of study enrollment allowed for RNAseq analysis on all patient samples evaluated. For purposes of this analysis, patients were categorized as achieving complete remission (CRs) or non-responders (NRs). CRs were defined as patients who achieved either complete remission or complete remission with incomplete hematologic recovery within 3 months and stayed in complete remission for at least one year after CAR infusion 1 . The cellular kinetics of tisagenlecleucel were determined as previously described 28 . A number of quality control metrics were assessed including data quality and GC content on per base and sequence levels, sequence length distribution and duplication levels, and insert size distribution. Finally, HTSeq was used to count the number of reads mapping to each gene 44 . Data normalization for differential expression analysis was carried out with the edgeR R package 45 . The logCPM value of each gene was z-normalized and gene set scores were calculated as the mean of the normalized gene expression for each gene in a given gene set. In order to account for the variability of the marrow blast count, the analysis was repeated and the gene set score was normalized to regress out the blast percentage.
To identify a threshold gene set score with high positive and negative predictive value of clinical outcomes, we performed receiver operating curve (ROC) analysis on the cohort of gene set scores.
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Statistical analysis: All comparisons between two groups were performed using either a twotailed unpaired Student's t-test or Mann-Whitney test, depending on normality of distribution.
Comparisons between more than two groups were performed by two-way analysis of variance (ANOVA) with Bonferroni correction for multiple comparisons. All results are represented as mean  standard error of the mean (s.e.m.). Survival data were analyzed using the Log-Rank (Mantel-Cox) test.
Data availability: Guide library sequencing, RNA sequencing and ATAC sequencing data are available from Gene Expression Omnibus (GEO) using the accession number GSE130663 for all data sets. RNAseq and ATACseq expression data are included in Supplementary Table 2 . Other data generated from this manuscript are available from the corresponding authors upon reasonable request. . d, Gene set enrichment analysis of the most-enriched and most-depleted sgRNAs identi ed in the short-term screen using the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database. e, Nalm6 cells edited for knockout of either FADD or BID were exposed to CART19 cells. f-g, immunodecient mice were engrafted with WT, FADD or BID KO Nalm6 and given 5x10 5 control T cells or CART19, and survival was measured over time. *P<0.05, **P<0.01, ***P<0.001 ****P<0.0001 by ANOVA (e) and Log-Rank test (f-g). KO or CD19 neg Nalm6 cells were co-cultured with CART19 cells and T cell expansion was measured over time. b, Schematic of functional evaluation studies, in which CART19 cells were sorted after short-term (5 day) and long-term (15 day) initial culture with either Nalm6 WT or BID KO and then re-exposed to Nalm6 WT in secondary cultures. Measurement of e ector functions including c,f, CART19 expansion after 48 and 120h of secondary culture, d,g, cytokine secretion after 48 hours, and e,h, Nalm6 survival after 48 and 120h of secondary culture. i, Principal component analysis of gene expression pro les CART19 cells at rest or after 15 days of exposure to Nalm6 WT or BID KO . j, Volcano plot of di erentially expressed genes in CART19 cells after exposure to Nalm6 WT or BID KO . Transcripts with log-fold change >0.5 and FDR >0.05 are shown in red. k, Heatmap of di erentially accessible chromatin sites in CART19 cells at rest or after exposure to WT or BID KO Nalm6 *P<0.05, **P<0.01, ***P<0.001 by ANOVA. Nalm6 count 3  2  1  0  -1  -2  -3   RIPK1  TNFRSF10A  TRADD  TNFRSF1B  TNFRSF25  FAF1  FAS  CASP10  CASP8  RIPK3  FADD  TNFRSF9  BID  CASP3  CASP7  TNFRSF10B Days after T cell delivery 17 20 Nalm6 WT + control Nalm6 WT + CART19 analyzed for b, perforin, c, granzyme B, d, IL-5, e, IL-13, or f, MIP1α. g-n, representative ow cytometry plots of sorted CART19 cells re-exposed to Nalm6 WT cells after g-j, short-term or k-n, long-term initial exposures. Hours in co-culture KO or PRF1 KO ) were sorted after short-term (5 day) and long-term (15 day) initial culture with WT Nalm6, and then re-exposed to WT Nalm6. Measurement of d,f, CART19 expansion over time and e,g, e ector cytokine secretion after 48 hours of re-exposure. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by ANOVA. NR   APAF1  BCL2L1  BAX  PPP3R1  PPP3CB  CAPN2  CASP3  PPP3CC  CYCS  CASP7  CASP9  TP53  PPP3R2  BAD  AIFM1  CHP2  PPP3CA  BAK1  BCL2L11 
